Lucas N Amenga-Etego1, Victor Asoala2, Godfred Agongo2, Christopher Jacob3, Sonia Goncalves3, Gordon A Awandare4, Kirk A Rockett3,5, Dominic Kwiatkowski5,6. 1. West African Centre for Cell Biology of Infectious Pathogens, Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Legon, Accra, Ghana. lamenga-etego@ug.edu.gh. 2. Navrongo Health Research Centre, Ghana Health Service, P. O. Box 114, Navrongo, Ghana. 3. Wellcome Centre for Human Genetics, University of Oxford, Headington, Oxford, OX3 7BN, UK. 4. West African Centre for Cell Biology of Infectious Pathogens, Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Legon, Accra, Ghana. 5. Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire, UK. 6. Big Data Institute, University of Oxford, Oxford, UK.
Abstract
BACKGROUND: Anti-malarial drug resistance remains a key concern for the global fight against malaria. In Ghana sulfadoxine-pyrimethamine (SP) is used for intermittent preventive treatment of malaria in pregnancy and combined with amodiaquine for Seasonal Malaria Chemoprevention (SMC) during the high malaria season. Thus, surveillance of molecular markers of SP resistance is important to guide decision-making for these interventions in Ghana. METHODS: A total of 4469 samples from uncomplicated malaria patients collected from 2009 to 2018 was submitted to the Wellcome Trust Sanger Institute, UK for DNA sequencing using MiSeq. Genotypes were successfully translated into haplotypes in 2694 and 846 mono infections respectively for pfdhfr and pfdhps genes and the combined pfhdfr/pfdhps genes across all years. RESULTS: At the pfdhfr locus, a consistently high (> 60%) prevalence of parasites carrying triple mutants (IRNI) were detected from 2009 to 2018. Two double mutant haplotypes (NRNI and ICNI) were found, with haplotype NRNI having a much higher prevalence (average 13.8%) than ICNI (average 3.2%) across all years. Six pfdhps haplotypes were detected. Of these, prevalence of five fluctuated in a downward trend over time from 2009 to 2018, except a pfdhps double mutant (AGKAA), which increased consistently from 2.5% in 2009 to 78.2% in 2018. Across both genes, pfdhfr/pfdhps combined triple (NRNI + AAKAA) mutants were only detected in 2009, 2014, 2015 and 2018, prevalence of which fluctuated between 3.5 and 5.5%. The combined quadruple (IRNI + AAKAA) genotype increased in prevalence from 19.3% in 2009 to 87.5% in 2011 before fluctuating downwards to 19.6% in 2018 with an average prevalence of 37.4% within the nine years. Prevalence of parasites carrying the quintuple (IRNI + AGKAA or SGEAA) mutant haplotypes, which are highly refractory to SP increased over time from 14.0% in 2009 to 89.0% in 2016 before decreasing to 78.9 and 76.6% in 2017 and 2018 respectively. Though quintuple mutants are rising in prevalence in both malaria seasons, together these combined genotypes vary significantly within season but not between seasons. CONCLUSIONS: Despite high prevalence of pfdhfr triple mutants and combined pfdhfr/pfdhps quadruple and quintuple mutants in this setting SP may still be efficacious. These findings are significant as they highlight the need to continuously monitor SP resistance, particularly using deep targeted sequencing to ascertain changing resistance patterns.
BACKGROUND: Anti-malarial drug resistance remains a key concern for the global fight against malaria. In Ghana sulfadoxine-pyrimethamine (SP) is used for intermittent preventive treatment of malaria in pregnancy and combined with amodiaquine for Seasonal Malaria Chemoprevention (SMC) during the high malaria season. Thus, surveillance of molecular markers of SP resistance is important to guide decision-making for these interventions in Ghana. METHODS: A total of 4469 samples from uncomplicated malaria patients collected from 2009 to 2018 was submitted to the Wellcome Trust Sanger Institute, UK for DNA sequencing using MiSeq. Genotypes were successfully translated into haplotypes in 2694 and 846 mono infections respectively for pfdhfr and pfdhps genes and the combined pfhdfr/pfdhps genes across all years. RESULTS: At the pfdhfr locus, a consistently high (> 60%) prevalence of parasites carrying triple mutants (IRNI) were detected from 2009 to 2018. Two double mutant haplotypes (NRNI and ICNI) were found, with haplotype NRNI having a much higher prevalence (average 13.8%) than ICNI (average 3.2%) across all years. Six pfdhps haplotypes were detected. Of these, prevalence of five fluctuated in a downward trend over time from 2009 to 2018, except a pfdhps double mutant (AGKAA), which increased consistently from 2.5% in 2009 to 78.2% in 2018. Across both genes, pfdhfr/pfdhps combined triple (NRNI + AAKAA) mutants were only detected in 2009, 2014, 2015 and 2018, prevalence of which fluctuated between 3.5 and 5.5%. The combined quadruple (IRNI + AAKAA) genotype increased in prevalence from 19.3% in 2009 to 87.5% in 2011 before fluctuating downwards to 19.6% in 2018 with an average prevalence of 37.4% within the nine years. Prevalence of parasites carrying the quintuple (IRNI + AGKAA or SGEAA) mutant haplotypes, which are highly refractory to SP increased over time from 14.0% in 2009 to 89.0% in 2016 before decreasing to 78.9 and 76.6% in 2017 and 2018 respectively. Though quintuple mutants are rising in prevalence in both malaria seasons, together these combined genotypes vary significantly within season but not between seasons. CONCLUSIONS: Despite high prevalence of pfdhfr triple mutants and combined pfdhfr/pfdhps quadruple and quintuple mutants in this setting SP may still be efficacious. These findings are significant as they highlight the need to continuously monitor SP resistance, particularly using deep targeted sequencing to ascertain changing resistance patterns.
Authors: James G Kublin; Fraction K Dzinjalamala; Deborah D Kamwendo; Elissa M Malkin; Joseph F Cortese; Lisa M Martino; Rabia A G Mukadam; Stephen J Rogerson; Andres G Lescano; Malcolm E Molyneux; Peter A Winstanley; Phillips Chimpeni; Terrie E Taylor; Christopher V Plowe Journal: J Infect Dis Date: 2002-01-17 Impact factor: 5.226
Authors: Abraham Rexford Oduro; George Wak; Daniel Azongo; Cornelius Debpuur; Peter Wontuo; Felix Kondayire; Paul Welaga; Ayaga Bawah; Alex Nazzar; John Williams; Abraham Hodgson; Fred Binka Journal: Int J Epidemiol Date: 2012-08 Impact factor: 7.196
Authors: Maxwell Appawu; Seth Owusu-Agyei; Samuel Dadzie; Victor Asoala; Francis Anto; Kwadwo Koram; William Rogers; Francis Nkrumah; Stephen L Hoffman; David J Fryauff Journal: Trop Med Int Health Date: 2004-01 Impact factor: 2.622
Authors: Elena R Lozovsky; Thanat Chookajorn; Kyle M Brown; Mallika Imwong; Philip J Shaw; Sumalee Kamchonwongpaisan; Daniel E Neafsey; Daniel M Weinreich; Daniel L Hartl Journal: Proc Natl Acad Sci U S A Date: 2009-07-08 Impact factor: 11.205
Authors: Nnaemeka C Iriemenam; Monica Shah; Wangeci Gatei; Anna M van Eijk; John Ayisi; Simon Kariuki; Jodi Vanden Eng; Simon O Owino; Ashima A Lal; Yusuf O Omosun; Kephas Otieno; Meghna Desai; Feiko O ter Kuile; Bernard Nahlen; Julie Moore; Mary J Hamel; Peter Ouma; Laurence Slutsker; Ya Ping Shi Journal: Malar J Date: 2012-07-04 Impact factor: 2.979
Authors: Hsiao-Han Chang; Colin J Worby; Adoke Yeka; Joaniter Nankabirwa; Moses R Kamya; Sarah G Staedke; Grant Dorsey; Maxwell Murphy; Daniel E Neafsey; Anna E Jeffreys; Christina Hubbart; Kirk A Rockett; Roberto Amato; Dominic P Kwiatkowski; Caroline O Buckee; Bryan Greenhouse Journal: PLoS Comput Biol Date: 2017-01-26 Impact factor: 4.475
Authors: Simon Kasasa; Victor Asoala; Laura Gosoniu; Francis Anto; Martin Adjuik; Cletus Tindana; Thomas Smith; Seth Owusu-Agyei; Penelope Vounatsou Journal: Malar J Date: 2013-02-13 Impact factor: 2.979